• Introduction to Cancer Therapy
• 36 min
  1. Early detection of lung cancer

  • Prof. Stephen Lam
• 46 min
  2. Development of a cancer drug

  • Prof. Martin Edelman
• Use of Novel "Targeted" Agents in Combination with Classical Cytotoxic Chemotherapy
• 60 min
  3. Cytotoxic chemotherapy

  • Dr. Michael Sawyer
• 35 min
  4. Small molecule inhibitors of receptor tyrosine kinases

  • Dr. Daniela Krause
• Innovative Strategies of Clinical Drug Development
• 46 min
  5. Phase II trials

  • Dr. Patricia Tang
• 33 min
  6. Surrogate endpoints of efficacy

  • Prof. Maurie Markman
• Biomarkers in Oncology: Rationale Development and Current Use
• 27 min
  7. Biomarkers in oncology: overview

  • Prof. Joe Duffy
• 55 min
  8. Genetic polymorphism of thiopurine methyltransferase and thiopurine therapy: from molecular genetics to clinical medicine

  • Dr. William Evans
• Archived Lectures *These may not cover the latest advances in the field
• 42 min
  9. Emerging trends in phase II trial design

  • Dr. Patricia Tang
• 36 min
  10. EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients

  • Prof. Fred Hirsch
• 36 min
  11. Therapy in cancer 2008: quo vadis?

  • Dr. Jeffrey Clark
• 34 min
  12. Changing paradigms in anticancer drug development: inhibiting angiogenesis in colorectal cancer

  • Prof. David Kerr
• 32 min
  13. Phase III trials

  • Prof. Martin Edelman
• 43 min
  14. Germline pharmacogenomics as a tool to individualize therapy in breast cancer

  • Dr. David Flockhart
• 33 min
  15. Gene profiling in breast cancer

  • Dr. Enrique Espinosa
• 31 min
  16. UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients

  • Prof. Tae Won Kim
• 28 min
  17. Principles of cancer treatment: surgery, radiotherapy, chemotherapy, immunotherapy

  • Dr. Theodore Yaeger
• 25 min
  18. Understanding cancer trends

  • Prof. Michael Thun
• 54 min
  19. Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

  • Dr. Tracey Evans
• 40 min
  20. Phase I study design for non-cytotoxic agents

  • Dr. Wendy Parulekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. EGFR TKIs in 2nd and 3rd line therapy
3. Activity of EGFR TKIs in unselected NSCLC
4. BR.21 study design
5. BR.21 overall survival
6. Forest plot of survival by subsets
7. Advantages for male smokers with SCC
8. ISEL: survival
9. Trials comparing Gefitinib to Docetaxel
10. Trial 0503 SIGN design
11. SIGN: objective response rate
12. SIGN: progression free survival
13. SIGN: overall survival
14. SIGN: quality of life and symptom improvement
15. Japanese study V-15-32 design
16. V-15-32: objective tumor response (RECIST)
17. V-15-32: progression free survival
18. V-15-32: overall survival (ITT)
19. V-15-32: QoL and symptom improvement
20. V-15-32: post study treatment
21. INTEREST: study design
22. INTEREST: overall survival
23. INTEREST: OS in EGFR FISH+ patients
24. Objective response in EGFR FISH+ patients
25. INTEREST: objective tumor response (RECIST)
26. INTEREST: QoL and symptom improvement
27. INTEREST: post discontinuation treatment
28. EGFR TKIs in 2nd/3rd line therapy - conclusions
29. EGFR inhibitors in 1st line therapy
30. Randomized trials of CT +/- EGFR TKIs
31. Maintenance Gefitinib WJTOG 0203 - design
32. Maintenance Gefitinib WJTOG 0203 - PFS
33. Maintenance Gefitinib WJTOG 0203 - OS
34. Cetuximab in NSCLC (1)
35. BMS099: Cetuximab with Taxane/Carboplatin
36. BMS099 treatment schedual and doses
37. BMS099: progression free survival
38. FLEX: Cetuximab plus Cis/Vin
39. FLEX efficacy results ITT
40. Asian subgroup efficacy results
41. EGFR inhibitors in lung cancer
42. EGFR TK domain mutations in NSCLC
43. Distribution of mutations in the TK domain
44. 1st line studies in patients with EGFR mutations
45. Percent change in measurable tumor
46. Progression free and overall survival
47. Effect of Gefitinib on patients with EGFR mutations
48. OS in patients with WT and mutant EGFR
49. Mutation subtypes and outcome
50. EGFR mutations are prognostic
51. Acquired resistance mechanisms to EGFR TKIs
52. EGFR in NSCLC - 4 categories
53. FISH predicts benefit of EGFR TKIs
54. BR2.1 OS - analysis of EGFR and Ras
55. Cetuximab in NSCLC
56. S0342: CT + concurrent or sequential Cetuximab
57. S0342: EGFR Gene Copy Number (FISH)
58. S0342: analysis by EGFR FISH - OS and PFS
59. S0342: concurrent vs. sequential
60. S0819: proposed SWOG Phase III, CT+Cetuximab
61. MARVEL: predictive marker study design
62. IHC and EGFR status: score system
63. BR.21 and ISEL: survival according to EGFR IHC
64. Combined SWOG/ITALIAN cohorts
65. Tarceva as a single agent or with chemotherapy
66. RADIANT: Tarceva adjuvant trial
67. Finding a serum based biomarker
68. Validation study
69. Blinded validation in E3503
70. Gefitinib sensitive/resistant cell lines
71. E-cadherin expression in NSCLC cell lines
72. EGFR interacting molecules
73. Synergistic effect of MS-275 and EGFR TKI in vitro
74. Phase I/II study combining Tarceva and SYN275

Topics Covered

• USAEGFR TKIs in 2nd /3rd line therapy
• Phase II activity of EGFR TKIs in unselected NSCLC
• BR.21 study design and overall survival
• Forest plot of survival by subsets
• Is there a survival advantage for male smokers with squamous-cell carcinoma?
• Trials comparing Gefitinib to Docetaxel
• SIGN trial
• RECIST study
• INTEREST study
• EGFR inhibitors in first line therapy
• Randomized Trials of CT+/- active targeted Rx
• Maintenance of Gefitinib WJTOG 0203
• Cetuximab in NSCLC
• EGFR interacting molecules

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on January 6, 2009
• Archived on June 22, 2016

Financial Disclosures

• Prof. Fred Hirsch has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.